首页> 外文期刊>Atherosclerosis >Metabolic syndrome (MetS) predicts cardio and cerebrovascular events in a twenty years follow-up. A prospective study
【24h】

Metabolic syndrome (MetS) predicts cardio and cerebrovascular events in a twenty years follow-up. A prospective study

机译:代谢综合症(MetS)预测在20年的随访中会出现心脑血管事件。前瞻性研究

获取原文
获取原文并翻译 | 示例
           

摘要

Background and purpose: Metabolic syndrome (MetS) is a cluster of cardiovascular risk factors, considered as emerging and promoting atherosclerosis.This study aimed at the evaluation of the influence of MetS on the prediction of cerebro and cardiovascular events during a 20 years follow-up period in an asymptomatic population of middle-aged subjects. Methods: We evaluated 529 asymptomatic persons through a prospective study. Study population was divided into two subgroups: patients with and without MetS. Echo-color-Doppler was used in order to assess the presence of subclinical atherosclerosis.A 20 years follow-up study was carried out in order to estimate the incidence of cerebro and cardiovascular, fatal and non fatal, events (AMI, stroke, abdominal aortic aneurysm, TIA, angina pectoris). Results: 242 cerebro and cardiovascular events were registered, 43 fatal (24 in MetS and 19 in controls) and 199 non fatal (120 with MetS and 79 without it, p < 0.0001). Free-events survival was lower in patients suffering from MetS ( p < 0.0012; HR 0.6847; C.I.95%: 0.5274-0.8889). Ultrasound showed a higher prevalence of subclinical atherosclerosis in patients with MetS than in the unaffected ones (68.12% vs. 57.5% p < 0.01; OR = 1.58 with C.I.95% = 1.10-2.28, p < 0.01). Conclusions: Patients with MetS have a higher cardiovascular risk that can be explained by atherosclerotic changes: the components of MetS interact to affect vascular thickness synergistically and promote the development of subclinical atherosclerosis. So we recommend to prevent the development of MetS abnormalities and to investigate the presence of subclinical atherosclerosis by echo-color-Doppler in order to stratify more accurately the global CV risk.
机译:背景与目的:代谢综合症(MetS)是一类心血管危险因素,被认为是正在发生并促进动脉粥样硬化的疾病。本研究旨在评估MetS对20年随访中脑和心血管事件预测的影响无症状的中年人时期。方法:我们通过一项前瞻性研究评估了529名无症状者。研究人群分为两个亚组:有和没有MetS的患者。使用Echo-color-Doppler评估亚临床动脉粥样硬化的存在。进行了20年的随访研究,以评估脑和心血管疾病的发生,致命和非致命,事件(AMI,中风,腹部)的发生率主动脉瘤,TIA,心绞痛)。结果:记录了242例脑和心血管事件,致命43例(在MetS中为24例,对照组为19例)和199例非致命(在MetS中为120例,未在MetS中为79例,p <0.0001)。患有MetS的患者的自由事件生存率较低(p <0.0012; HR 0.6847; C.I.95%:0.5274-0.8889)。超声显示MetS患者的亚临床动脉粥样硬化患病率高于未受影响的患者(68.12%比57.5%p <0.01; OR = 1.58,C.I.95%= 1.10-2.28,p <0.01)。结论:MetS患者具有较高的心血管风险,可以用动脉粥样硬化的变化来解释:MetS的成分相互作用以协同影响血管厚度并促进亚临床动脉粥样硬化的发展。因此,我们建议防止MetS异常的发生,并通过echo-color-Doppler调查亚临床动脉粥样硬化的存在,以便更准确地对全球CV风险进行分层。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号